AbbVie Sees Positive Results in Rinvoq Studies
October 07 2021 - 9:26AM
Dow Jones News
By Robb M. Stewart
AbbVie Inc. on Thursday reported positive top-line results from
two studies of an investigational once-daily treatment for patients
with active ankylosing spondylitis and non-radiographic axial
spondyloarthritis.
In a late-stage clinical trial evaluating the efficacy and
safety of Rinvoq in patients with active ankylosing spondylitis who
had an inadequate response to biologic DMARD therapy, the company
said the treatment met its primary endpoint. Significantly more
Rinvoq-treated patients achieved ASAS40 response at week 14
compared with a placebo, AbbVie said.
Ankylosing spondylitis is a debilitating disease that can cause
severe pain, stiffness, restricted mobility and lasting structural
damage. Michael Severino, vice chairman and president of AbbVie,
said the results show Rinvoq was able to provide significant
improvements in signs and symptoms, as well as other measures of
disease activity, for patients living with ankylosing spondylitis
who have already failed treatment with a biologic.
Treatment with Rinvoq resulted in statistically significant
reductions in signs and symptoms of ankylosing spondylitis,
including back pain and inflammation, as well as improvements in
physical function and disease activity at week 14, the company
said.
In study two, AbbVie said upadacitinib, or Rinvoq, met the
primary endpoint of assessment in SpondyloArthritis International
Society 40 response and 12 of 14 ranked secondary endpoints at week
14. Treatment with Rinvoq resulted in reductions in signs and
symptoms of non-radiographic axial spondyloarthritis, including
back pain and inflammation, as well as improvements in physical
function and disease activity at week 14, it said.
Non-radiographic axial spondyloarthritis affects a younger adult
patient population.
Full results from the Select-Axis 2 trial will be presented at a
future medical meeting and submitted for publication in a
peer-reviewed journal, the company said.
In premarket trading, AbbVie's shares were trading 0.9% higher
after ending Wednesday at $109.32, up 2% since the end of last
year.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
October 07, 2021 09:11 ET (13:11 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024